Teva’s NTE Strategy Initially Emphasizes Pain, Glaucoma, Schizophrenia
This article was originally published in The Pink Sheet Daily
Teva seeks to leverage its “new therapeutic entities” strategy devised under the regime of now-departed CEO Jeremy Levin in order to bolster revenues as it maneuvers through the patent expiration of its most profitable product, Copaxone, in May 2014.
You may also be interested in...
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.